Trial Profile
Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Tolcapone (Primary)
- Indications Amyloid polyneuropathy
- Focus Pharmacodynamics; Proof of concept
- Sponsors SOM Biotech
- 29 Nov 2016 Status changed from recruiting to completed.
- 21 Apr 2016 Results of Phase IIa part (n=21) presented at the 68th Annual Meeting of the American Academy of Neurology.
- 26 May 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Jul 2015, according to to ClinicalTrials.gov record.